Pacific biosciences of california stock.

Nov 6, 2023 · These 9 analysts have an average price target of $11.22 versus the current price of Pacific Biosciences at $7.2, implying upside. Below is a summary of how these 9 analysts rated Pacific ... Pacific Biosciences of California last issued its quarterly earnings results on October 30th, 2023. The biotechnology company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.02. The business earned $55.70 million during the quarter, compared to analyst estimates of $48.76 million.Nov 16, 2023 · Get the latest Pacific Biosciences of California Inc. (PACB) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. Mar 31, 2023 · Pacific Biosciences of California Inc’s price is currently up 27.53% so far this month. During the month of March, Pacific Biosciences of California Inc’s stock price has reached a high of $11.79 and a low of $8.01. Over the last year, Pacific Biosciences of California Inc has hit prices as high as $14.20 and as low as $3.85.

Pacific Biosciences of California Stock Forecast 11-26-2023. Forecast target price for 11-26-2023: $ 8.02. Negative dynamics for Pacific Biosciences of California shares will prevail with possible volatility of 5.469%. Pessimistic target level: 7.80.MENLO PARK, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, highly accurate sequencing platforms, today announced a partnership with The European Reference Genome Atlas (ERGA) consortium to support …Jan 9, 2023 · Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists ...

US Stock MarketDetailed Quotes. PACB Pacific Biosciences of California. Close 11/13 16:00 ET. 6.440. -0.080 -1.23%. High 6.525. Low 6.175. Volume4.80M. Post ...Currently, the analyst consensus on Pacific Biosciences is a Hold with an average price target of $11.40. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $14.20 and a ...

Pacific Biosciences of California's (PACB) CEO Mike Hunkapiller on Q4 2015 Results - Earnings Call Transcript SA Transcripts Wed, Feb. 03, 2016 Pacific Biosciences of California (PACB) Q4 2015 ...Complete Pacific Biosciences of California Inc. stock information by Barron's. View real-time PACB stock price and news, along with industry-best analysis. Transcript : Pacific Biosciences of California, Inc. Presents at UBS MedTech, Tools and Genomics Summit 2023, Aug-16-2023 04:00 PM Aug. 16: CI Pacific Biosciences of California, GeneDx Partner With University of Washington to Study Long-Read Sequencing Aug. 07: MTKGI Securities started coverage on Pacific Biosciences of California and gave it an “outperform” rating in their report released on Wednesday June 7th. Morgan Stanley increased its price target for Pacific Biosciences of California from $12.00 to $13.00 and gave the stock an “equal weight” rating in their report on Thursday, August 3rd.

Nov 27, 2023 · The average twelve-month price prediction for Pacific Biosciences of California is $11.80 with a high price target of $17.00 and a low price target of $8.00. Learn more on PACB's analyst rating history. Do Wall Street analysts like Pacific Biosciences of California more than its competitors?

٣٠‏/٠٨‏/٢٠٢٣ ... Pacific Biosciences of California (PacBio; PACB) shares have doubled year-over-year, zooming 101% despite a 26% decline earlier this month.

Pacific Biosciences of California stock monthly and weekly forecasts. Skip to content. FORECST.COM 2023 – 2026 Stock Market Forecast PACB stock forecast for 2023 – 2027. Last updated: October 11, 2023. Are you interested in Pacific Biosciences of California, Inc. stocks prediction?Get the latest PACB stock quote, news, history and other vital information to help you with your stock trading and investing. See the performance outlook, earnings date, dividend yield, insider transactions and related research of Pacific Biosciences of California, Inc. (PACB) on NasdaqGS.Pacific Biosciences Of California. stock was originally listed at a price of $16.44 in Oct 27, 2010. If you had invested in Pacific Biosciences Of California stock at $16.44 , your return over the last 13 years would have been -47.99% , for an annualized return of -4.9% (not including any dividends or dividend reinvestments).The Pacific Biosciences of California stock prediction for 2025 is currently $ 21.57, assuming that Pacific Biosciences of California shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 157.52% increase in the PACB stock price.Apr 30, 2021 · PacBio announced record first-quarter revenue of $29 million, an 86% year-over-year increase and exactly what analysts expected. Meanwhile, the company recorded a net loss of $87.4 million -- or a ... Pacific Biosciences of California, Inc. Q4 Loss Increases, but beats estimates. (RTTNews) - Pacific Biosciences of California, Inc. (PACB) released Loss for its fourth quarter that increased from ...

As of February 15, 2023, 4:00 PM CST, Pacific Biosciences of California Inc’s stock price was $11.09. Pacific Biosciences of California Inc is up 7.88% from its previous closing price of $10.28. During the last market session, Pacific Biosciences of California Inc’s stock traded between $9.75 and $10.47.The notes will have a conversion price of $43.50 per share of the company's common stock, representing a 10% premium over Pacific Biosciences' share price as of the end of yesterday's trading session.Pacific Biosciences of California Inc’s price is currently up 8.37% so far this month. During the month of March, Pacific Biosciences of California Inc’s stock price has reached a high of $10.00 and a low of $8.52. Over the last year, Pacific Biosciences of California Inc has hit prices as high as $14.20 and as low as $3.85.Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report)’s stock price dropped 4% on Monday .The company traded as low as $8.14 and last traded at $8.21. Approximately 282,223 ...PDF Version. MENLO PARK, Calif., Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it intends to offer and sell $150.0 million of shares of its common stock in an underwritten public offering. PacBio also intends to grant the underwriters a 30-day option to purchase up to an ...Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter and the Fiscal Year Ended December 31, 2021 Jan 12 Price target …Pacific Biosciences of California, Inc. (PACB) latest earnings report: revenue, EPS, surprise, history, news and analysis.

Complete Pacific Biosciences of California Inc. stock information by Barron's. View real-time PACB stock price and news, along with industry-best analysis. Pacific Biosciences of California Inc. Watch NEW Set a price target alert Premarket Last Updated: Nov 28, 2023 8:00 a.m. EST Delayed quote $ 8.44 0.00 0.00% Before Hours Volume: 1 Advanced...

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists ...We note from Pacific Biosciences of California Inc’s average daily trading volume that its 10-day average is 4.96 million shares, with the 3-month average coming to 4.63 million. Pacific Biosciences of California Inc stock received a consensus recommendation rating of an Overweight, based on a mean score of 1.58.Nov 21, 2023 · HENRY CHRISTIAN O, the of Pacific Biosciences of California Inc, sale 96,844 shares at $10.12 during a trade that took place back on Sep 18, which means that HENRY CHRISTIAN O is holding 1,106,095 shares at $980,255 based on the most recent closing price. Stock Fundamentals for PACB. Current profitability levels for the company are sitting at: ٠٧‏/٠٨‏/٢٠٢٣ ... 9/13/2023 Pacific Biosciences CA sees its Relative Strength Rating reach the... Pacific Biosciences of California Stock Clears Key Benchmark, ...Apr 21, 2023 · Valuation for Pacific Biosciences In 2023, the firm anticipates generating revenues in the range of $165 million to $180 million, reflecting a 29% to 40% increase. During the fourth quarter, 76 ... Pacific Biosciences of California (NASDAQ:PACB) ... The stock is currently trading at $7.59. UBS estimates ~34% revenue growth in 2024, and a revenue CAGR of 42% in 2022-2026.١٢‏/١٠‏/٢٠٢٣ ... Shares of Pacific Biosciences of California (PACB) - Get Free Report, a life science technology company focused on solving genetic problems, ...Pacific Biosciences (PACB) delivered earnings and revenue surprises of 23.53% and 17.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Pacific Biosciences of California (NASDAQ:PACB) rose 3.16% Friday pre-market after UBS upgraded the sequencing systems company on a strong "Revio" demand. Revio system is a product with long-read ...Discover Pacific Biosciences of California's earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. ... Independent Director exercised options and sold US$793k worth of stock May 29. The Pullback In Pacific Biosciences Makes For A Much More Interesting Opportunity …

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a California-based biotech firm founded in 2004. It is ranked seventh on our list of 10 best biotech stocks to buy according to Cathie Wood.

Pacific Biosciences of California Inc’s price is currently down 2.39% so far this month. During the month of September, Pacific Biosciences of California Inc’s stock price has reached a high of $11.96 and a low of $10.14. Over the last year, Pacific Biosciences of California Inc has hit prices as high as $14.55 and as low as $4.97.

One such stock that merits attention is Pacific Biosciences of California Inc (NASDAQ:PACB). The stock, which is currently priced at 10.06, recorded a loss of 3.5% in a day and a 3-month decrease ...In other news, insider Susan G. Kim sold 19,257 shares of Pacific Biosciences of California stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $8.44 ...Track Pacific Biosciences of California Inc (PACB) Stock Price, Quote, latest community messages, chart, news and other stock related information.Pacific Biosciences of California Stock Performance. Shares of NASDAQ PACB opened at $8.88 on Friday. The business has a fifty day simple moving average of $7.76 and a 200 day simple moving ...As of November 1, 2023, Canaccord Genuity analyst Kyle Mikson has reaffirmed a Buy rating on Pacific Biosciences (NASDAQ:PACB), although ... Best stocks to buy now; Categories. Crypto; Dow Jones today; Pre-IPO and startups; Tech stocks; Utility stocks; Best Stocks tools HOT. Stock News Sentiment;See Pacific Biosciences of California, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy.Common Stock, par value $0.001 per share. PACB. ... Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. The Company has developed Single Molecule, …Nov 21, 2023 · HENRY CHRISTIAN O, the of Pacific Biosciences of California Inc, sale 96,844 shares at $10.12 during a trade that took place back on Sep 18, which means that HENRY CHRISTIAN O is holding 1,106,095 shares at $980,255 based on the most recent closing price. Stock Fundamentals for PACB. Current profitability levels for the company are sitting at: Apr 21, 2023 · Valuation for Pacific Biosciences In 2023, the firm anticipates generating revenues in the range of $165 million to $180 million, reflecting a 29% to 40% increase. During the fourth quarter, 76 ...

24 Jan, 2023, 16:05 ET. MENLO PARK, Calif., Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it intends to offer and sell $150.0 ...Two of Cathie Wood's Ark Invest ETFs loaded up on shares of Pacific Biosciences of California (PacBio). PacBio is an innovative disruptor in the genetic sequencing market. However, the company ...Get the latest PACB stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's earnings, balance sheet, cash flow, and market cap for the second quarter of 2023.Instagram:https://instagram. sstkohio dental coveragewhat etf pays the highest monthly dividendteva pharmaceutical industries stock PacBio announced record first-quarter revenue of $29 million, an 86% year-over-year increase and exactly what analysts expected. Meanwhile, the company recorded a net loss of $87.4 million -- or a ... sabra reitvanguard s and p 500 mutual fund The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings. Price Target Upside/Downside. According to ...Institutional investors purchased a net $7.8 million shares of PACB during the quarter ended June 2019 and now own 98.90% of the total shares outstanding. This ... stock artificial intelligence Jan-26-23 08:52AM. Pacific Biosciences of California (NASDAQ:PACB) shareholder returns have been massive, earning 313% in 5 years. (Simply Wall St.) Jan-24-23 11:18PM. Pacific Biosciences of California, Inc. Announces Pricing of Upsized Public Offering of Common Stock. Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. The Company has developed Single Molecule, Real-Time (SMRT) technology, which …MENLO PARK, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced the appointment of Susan G. Kim as Chief Financial Officer, effective as of September 28, …